Please assess the completion status of the following clinical trial:

Trial Title: Safety of Autologous MSC Infusion to Treat Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of symptomatic epilepsy,~* Disease progression for the last 1-3 years,~* Resistance of epilepsy to therapy with carbamazepine, valproic acid, topiramate, lamotrigine, and phenobarbital (anti-epileptic drugs/AEDs) as monotherapies or combination therapies;~* Signed informed consent~Exclusion Criteria:~* Central nervous system inflammatory disorders (meningoencephalitis of viral or parasite origin),~* Chronic decompensated psychoses ,dementia, social disadaptation,~* Central nervous system tumours.~* Blood positivity for hepatitis B or C or HIV infection;~* According to the judgment of the researchers, subjects who were unable to complete the study or may not have been able to comply with the requirements of this study (due to administrative or other reasons).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs \[AEDs\]) and receiving autologous mesenchymal stem cells
- control group (Type: NO_INTERVENTION): Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)

Based on this trial design, predict the completion outcome and termination type (if applicable).